top of page
Browse by category
Search
12% of Americans have used GLP-1 weight loss drugs
Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to report from...
AMA passes resolution calling for expanded access to AOMs
The American Medical Association (AMA) House of Delegates has passed the Endocrine Society’s resolution to improve access to anti-obesity...
Medicare and Medicaid will not expand coverage to anti-obesity medications
The US Centers for Medicare & Medicaid Services (CMS) confirmed that it will not proceed with a Biden administration proposal to expand...
Expanding access to anti-obesity medications delivers 13% return on investment for society
A USC Schaeffer Center white paper entitled, ‘Lifetime Social Returns From Expanding Access to Anti-Obesity Medication’, finds expanded...
Medicare and other insurance should cover obesity drugs
A large majority of older Americans feel that health insurance - including Medicare - should cover anti-obesity medications, according to...
More than 65 organisations advocate for coverage of obesity care in open letter to leading employers as Obesity Care Week urges expanded coverage to include FDA-approved obesity medications
The Alliance for Women's Health and Prevention's (AWHP) EveryBODY Covered campaign delivered an open letter to executives at top...
More than half of US adults could benefit from GLP-1 medications
More than half of US adults, an estimated that 137 million people, are eligible for semagludtide for weight loss, diabetes management, or...
Omada survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals
Omada Health has released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers...
GLP-1s: Second year cost of care is $4,200 higher for patients with obesity
Individuals without diabetes who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for obesity experienced an average of $4,206...
GLP-1 use doubles as bariatric surgery declines by 25%
A study by researchers at Brigham and Women's Hospital, in collaboration with researchers at Harvard TH Chan School of Public Health and...
Browse by tag
bottom of page